Hippo 通路的失调是癌症进展和治疗耐药的驱动因素。在胃癌中，YAP1 是患者预后不良的生物标志物。尽管基因组肿瘤分析提供了 Hippo 通路激活的信息，但本研究表明，抑制 Yap1 活性对由致癌突变和炎症细胞因子驱动的胃肿瘤具有抗肿瘤作用。我们发现 Yap1 是正常和肿瘤性胃上皮细胞代谢、增殖和免疫反应的关键调节因子。我们认为 Hippo 通路可针对胃癌亚型，其治疗效果可能是由癌细胞内在和外在机制介导的。© 2023 Thilakasiri 等人。

Deregulation of the Hippo pathway is a driver for cancer progression and treatment resistance. In the context of gastric cancer, YAP1 is a biomarker for poor patient prognosis. Although genomic tumor profiling provides information of Hippo pathway activation, the present study demonstrates that inhibition of Yap1 activity has anti-tumor effects in gastric tumors driven by oncogenic mutations and inflammatory cytokines. We show that Yap1 is a key regulator of cell metabolism, proliferation, and immune responses in normal and neoplastic gastric epithelium. We propose that the Hippo pathway is targetable across gastric cancer subtypes and its therapeutic benefits are likely to be mediated by both cancer cell-intrinsic and -extrinsic mechanisms.© 2023 Thilakasiri et al.